Effects of ARHI on breast cancer cell biological behavior regulated by microRNA-221

Tumor Biology

Volumn 34, Issue 6, 2013, Pages 3545-3554

  Li, Ying ^a   Liu, Mei ^a   Zhang, Yanjun ^a   Han, Chun ^a   You, Junhao ^a   Yang, Junlan ^a   Cao, Cheng ^a   Jiao, Shunchang ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

ARHI; Breast cancer; miR 221

Indexed keywords

MICRORNA 221;

3' UNTRANSLATED REGION; APOPTOSIS; ARHI GENE; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENE IDENTIFICATION; GENE INTERACTION; GENE OVEREXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; RNA GENE; TUMOR INVASION; TUMOR SUPPRESSOR GENE; UPREGULATION;

EID: 84891488728     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-013-0933-6     Document Type: Article

References (52)

1. Wheeler SB, Reeder-Hayes K, Meyer AM. A balancing act for breast cancer? Everolimus for hormone receptor positive patients. Transl Cancer Res. 2012;1:109-12.
2. Dong X, Alpaugh KR, Cristofanilli M. Circulating tumor cells (CTCs) in breast cancer: a diagnostic tool for prognosis and molecular analysis. Chin J Cancer Res. 2012;24:388-98.
3. Lohmann AE, Saini KS, Metzger-Filho O. Pertuzumab in metastatic breast cancer: unanswered questions. Transl Cancer Res. 2012;1:122-4.
4. Rashid OM, Takabe K. The evolution of the role of surgery in the management of breast cancer lung metastasis. J Thorac Dis. 2012;4:420-4.
5. Ishikawa T, Shimizu D, Kito A, Ota I, Sasaki T, Tanabe M, et al. Breast cancer manifested by hematologic disorders. J Thorac Dis. 2012;4:650-4.
6. Smith HS, Wu SX. Persistent pain after breast cancer treatment. Ann Palliat Med. 2012;1:182-94.
7. Tamura K. Medical oncology in Asia. Chin Clin Oncol. 2012;1:2.
8. Ow S, Lee SC. Brain metastases in HER2 positive breast cancer: the next hurdle. Ann Palliat Med. 2012;1:198-201.
9. Li Q, Zhu F, Chen P. miR-7 and miR-218 epigenetically control tumor suppressor genes RASSF1A and Claudin-6 by targeting HoxB3 in breast cancer. Biochem Biophys Res Commun. 2012;424:28-33.
10. Romero-Cordoba S, Rodriguez-Cuevas S, Rebollar-Vega R, Quintanar-Jurado V, Maffuz-Aziz A, Jimenez-Sanchez G, et al. Identification and pathway analysis of microRNAs with no previous involvement in breast cancer. PLoS One. 2012;7:e31904.
11. Bargaje R, Gupta S, Sarkeshik A, Park R, Xu T, Sarkar M, et al. Identification of Novel Targets for miR-29a Using miRNA Proteomics. PLoS One. 2012;7:e43243.
12. Kang H, Louie J, Weisman A, Sheu-Gruttadauria J, Davis-Dusenbery BN, Lagna G, et al. Inhibition of microRNA-302 (miR-302) by bone morphogenetic protein 4 (BMP4) facilitates the BMP signaling pathway. J Biol Chem. 2012;287:38656-64.
13. Zeng Y, Yi R, Cullen BR. MicroRNAs and small interfering RNAs can inhibit mRNA expression by similar mechanisms. Proc Natl Acad Sci U S A. 2003;100:9779-84.
14. Keklikoglou I, Koerner C, Schmidt C, Zhang JD, Heckmann D, Shavinskaya A, et al. MicroRNA-520/373 family functions as a tumor suppressor in estrogen receptor negative breast cancer by targeting NF-kappaB and TGF-beta signaling pathways. Oncogene. 2012;31:4150-63.
15. Tang B, He WL, Zheng C, Cheang TY, Zhang XF, Wu H, et al. Marine fungal metabolite 1386A alters the microRNA profile in MCF-7 breast cancer cells. Mol Med Rep. 2012;5:610-8.
16. Chen J, Wang B. The roles of miRNA-143 in colon cancer and therapeutic implications. Transl Gastrointest Cancer. 2012;1:169-74.
17. Du L, Pertsemlidis A. microRNA regulation of cell viability and drug sensitivity in lung cancer. Expert Opin Biol Ther. 2012;12:1221-39.
18. He B, Yin B, Wang B, Xia Z, Chen C, Tang J. microRNAs in esophageal cancer (Review). Mol Med Rep. 2012;6:459-65.
19. Link A, Kupcinskas J, Wex T, Malfertheiner P. Macro-Role of MicroRNA in Gastric Cancer. Dig Dis. 2012;30:255-67.
20. Kong YW, Ferland-McCollough D, Jackson TJ, Bushell M. microRNAs in cancer management. Lancet Oncol. 2012;13:e249-58.
21. Cortez MA, Welsh JW, Calin GA. Circulating microRNAs as noninvasive biomarkers in breast cancer. Recent Results Cancer Res. 2012;195:151-61.
22. Pineau P, Volinia S, McJunkin K, Marchio A, Battiston C, Terris B, et al. miR-221 overexpression contributes to liver tumorigenesis. Proc Natl Acad Sci U S A. 2010;107:264-9.
23. Fu X, Wang Q, Chen J, Huang X, Chen X, Cao L, et al. Clinical significance of miR-221 and its inverse correlation with p27Kip(1) in hepatocellular carcinoma. Mol Biol Rep. 2011;38:3029-35.
24. Frenquelli M, Muzio M, Scielzo C, Fazi C, Scarfo L, Rossi C, et al. MicroRNA and proliferation control in chronic lymphocytic leukemia: functional relationship between miR-221/222 cluster and p27. Blood. 2010;115:3949-59.
25. Santhekadur PK, Das SK, Gredler R, Chen D, Srivastava J, Robertson C, et al. Multifunction protein staphylococcal nuclease domain containing 1 (SND1) promotes tumor angiogenesis in human hepatocellular carcinoma through novel pathway that involves nuclear factor kappaB and miR-221. J Biol Chem. 2012;287:13952-8.
26. Shen J, Hruby GW, McKiernan JM, Gurvich I, Lipsky MJ, Benson MC, et al. Dysregulation of circulating microRNAs and prediction of aggressive prostate cancer. Prostate. 2012;72:1469-77.
27. Park JK, Kogure T, Nuovo GJ, Jiang J, He L, Kim JH, et al. miR-221 silencing blocks hepatocellular carcinoma and promotes survival. Cancer Res. 2011;71:7608-16.
28. Howe EN, Cochrane DR, Richer JK. The miR-200 and miR-221/222 microRNA families: opposing effects on epithelial identity. J Mammary Gland Biol Neoplasia. 2012;17:65-77.
29. Lu Y, Roy S, Nuovo G, Ramaswamy B, Miller T, Shapiro C, et al. Anti-microRNA-222 (anti-miR-222) and -181B suppress growth of tamoxifen-resistant xenografts in mouse by targeting TIMP3 protein and modulating mitogenic signal. J Biol Chem. 2011;286:42292-302.
30. Stinson S, Lackner MR, Adai AT, Yu N, Kim HJ, O'Brien C, et al. miR-221/222 targeting of trichorhinophalangeal 1 (TRPS1) promotes epithelial-to-mesenchymal transition in breast cancer. Sci Signal. 2011;4. pt5.
31. Hanna JA, Wimberly H, Kumar S, Slack F, Agarwal S, Rimm DL. Quantitative analysis of microRNAs in tissue microarrays by in situ hybridization. Biotechniques. 2012;52:235-45.
32. Pasquinelli AE. MicroRNAs and their targets: recognition, regulation and an emerging reciprocal relationship. Nat Rev Genet. 2012;13:271-82.
33. Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, et al. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007;14:791-8.
34. Garofalo M, Di Leva G, Romano G, Nuovo G, Suh SS, Ngankeu A, et al. miR-221&222 regulate TRAIL resistance and enhance tumorigenicity through PTEN and TIMP3 downregulation. Cancer Cell. 2009;16:498-509.
35. Sun K, Wang W, Zeng JJ, Wu CT, Lei ST, Li GX. MicroRNA-221 inhibits CDKN1C/p57 expression in human colorectal carcinoma. Acta Pharmacol Sin. 2011;32:375-84.
36. Chen Y, Zaman MS, Deng G, Majid S, Saini S, Liu J, et al. MicroRNAs 221/222 and genistein-mediated regulation of ARHI tumor suppressor gene in prostate cancer. Cancer Prev Res (Phila). 2011;4:76-86.
37. Badgwell DB, Lu Z, Le K, Gao F, Yang M, Suh GK, et al. The tumor-suppressor gene ARHI (DIRAS3) suppresses ovarian cancer cell migration through inhibition of the Stat3 and FAK/Rho signaling pathways. Oncogene. 2012;31:68-79.
38. Yu Y, Xu F, Peng H, Fang X, Zhao S, Li Y, et al. NOEY2 (ARHI), an imprinted putative tumor suppressor gene in ovarian and breast carcinomas. Proc Natl Acad Sci U S A. 1999;96:214-9.
39. Zou CF, Jia L, Jin H, Yao M, Zhao N, Huan J, et al. Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer. 2011;11:22.
40. Janssen EA, Ovestad IT, Skaland I, Soiland H, Gudlaugsson E, Kjellevold KH, et al. LOH at 1p31 (ARHI) and proliferation in lymph node-negative breast cancer. Cell Oncol. 2009;31:335-43.
41. Li Y, Shi L, Han C, Wang Y, Yang J, Cao C, et al. Effects of ARHI on cell cycle progression and apoptosis levels of breast cancer cells. Tumour Biol. 2012;33:1403-10.
42. Tanner M, Kapanen AI, Junttila T, Raheem O, Grenman S, Elo J, et al. Characterization of a novel cell line established from a patient with Herceptin-resistant breast cancer. Mol Cancer Ther. 2004;3:1585-92.
43. Qin XJ, Ling BX. Proteomic studies in breast cancer (Review). Oncol Lett. 2012;3:735-43.
44. Wei F, Xu J, Tang L, Shao J, Wang Y, Chen L, et al. p27(Kip1) V109G Polymorphism and Cancer Risk: A Systematic Review and Meta-Analysis. Cancer Biother Radiopharm. 2012;27:665-71.
45. Wedam SB, Yang SX. Neoadjuvant bevacizumab and chemotherapyin breast cancer. Transl Cancer Res. 2012;1:57-8.
46. Tang HL, Hu YQ, Qin XP, Jazag A, Yang H, Yang YX, et al. Aplasia ras homolog member I is downregulated in gastric cancer and silencing its expression promotes cell growth in vitro. J Gastroenterol Hepatol. 2012;27:1395-404.
47. Lin D, Cui F, Bu Q, Yan C. The expression and clinical significance of GTP-binding RAS-like 3 (ARHI) and microRNA 221 and 222 in prostate cancer. J Int Med Res. 2011;39:1870-5.
48. Pei XH, Yang Z, Liu HX, Qiao SS. Aplasia Ras homologue member I overexpression induces apoptosis through inhibition of survival pathways in human hepatocellular carcinoma cells in culture and in xenograft. Cell Biol Int. 2011;35:1019-24.
49. Peng H, Xu F, Pershad R, Hunt KK, Frazier ML, Berchuck A, et al. ARHI is the center of allelic deletion on chromosome 1p31 in ovarian and breast cancers. Int J Cancer. 2000;86:690-4.
50. Yuan J, Luo RZ, Fujii S, Wang L, Hu W, Andreeff M, et al. Aberrant methylation and silencing of ARHI, an imprinted tumor suppressor gene in which the function is lost in breast cancers. Cancer Res. 2003;63:4174-80.
51. Fujii S, Luo RZ, Yuan J, Kadota M, Oshimura M, Dent SR, et al. Reactivation of the silenced and imprinted alleles of ARHI is associated with increased histone H3 acetylation and decreased histone H3 lysine 9 methylation. Hum Mol Genet. 2003;12:1791-800.
52. Thorsen SB, Obad S, Jensen NF, Stenvang J, Kauppinen S. The therapeutic potential of microRNAs in cancer. Cancer J. 2012;18(3):275-84.